Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Disability outcome measures in multiple sclerosis clinical trials : current status and future prospects. / Cohen, Jeffrey A; Reingold, Stephen C; Polman, Chris H; Wolinsky, Jerry S; International Advisory Committee on Clinical Trials in Multiple Sclerosis ; Sørensen, Per Soelberg.
In: Lancet Neurology, Vol. 11, No. 5, 2012, p. 467-76.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Disability outcome measures in multiple sclerosis clinical trials
T2 - current status and future prospects
AU - Cohen, Jeffrey A
AU - Reingold, Stephen C
AU - Polman, Chris H
AU - Wolinsky, Jerry S
AU - International Advisory Committee on Clinical Trials in Multiple Sclerosis
AU - Sørensen, Per Soelberg
N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.
PY - 2012
Y1 - 2012
N2 - Many of the available disability outcome measures used in clinical trials of multiple sclerosis are insensitive to change over time, inadequately validated, or insensitive to patient-perceived health status or quality of life. Increasing focus on therapies that slow or reverse disability progression makes it essential to refine existing measures or to develop new tools. Major changes to the expanded disability status scale should be avoided to prevent the loss of acceptance by regulators as a measure for primary outcomes in trials that provide substantial evidence of effectiveness. Rather, we recommend practical refinements. Conversely, although substantial data support the multiple sclerosis functional composite as an alternative measure, changes to its component tests and scoring method are needed. Novel approaches, including the use of composite endpoints, patient-reported outcomes, and measurement of biomarkers, show promise as adjuncts to the current disability measures, but are insufficiently validated to serve as substitutes. A collaborative approach that involves academic experts, regulators, industry representitives, and funding agencies is needed to most effectively develop disability outcome measures.
AB - Many of the available disability outcome measures used in clinical trials of multiple sclerosis are insensitive to change over time, inadequately validated, or insensitive to patient-perceived health status or quality of life. Increasing focus on therapies that slow or reverse disability progression makes it essential to refine existing measures or to develop new tools. Major changes to the expanded disability status scale should be avoided to prevent the loss of acceptance by regulators as a measure for primary outcomes in trials that provide substantial evidence of effectiveness. Rather, we recommend practical refinements. Conversely, although substantial data support the multiple sclerosis functional composite as an alternative measure, changes to its component tests and scoring method are needed. Novel approaches, including the use of composite endpoints, patient-reported outcomes, and measurement of biomarkers, show promise as adjuncts to the current disability measures, but are insufficiently validated to serve as substitutes. A collaborative approach that involves academic experts, regulators, industry representitives, and funding agencies is needed to most effectively develop disability outcome measures.
U2 - 10.1016/S1474-4422(12)70059-5
DO - 10.1016/S1474-4422(12)70059-5
M3 - Journal article
VL - 11
SP - 467
EP - 476
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 5
ER -
ID: 48584376